Enhancing plasticity through repeated rTMS sessions: The benefits of a night of sleep

Cohen, Daniel; Freitas, Catarina; Tormos, José; Oberman, Lindsay M.; Eldaief, Mark C.; Pascual‐Leone, Álvaro

doi:10.1016/j.clinph.2010.05.019

Cited by 24 publications

(16 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of narcolepsy, regenerative therapies for the hypocretin system, which undergoes degeneration in narcolepsy, are worthy of attention and effort (102, 103). In addition, transcranial manipulation of the electrical activity of the cerebral cortex (ultimately the seat of fatigue-related deficits) for therapeutic intervention is fast becoming a reality (104, 105). …”

Section: Resultsmentioning

confidence: 99%

Modafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered Questions

Wisor¹

2013

Front. Neurol.

View full text Add to dashboard Cite

Modafinil, in its two clinical formulations (Provigil® and Nuvigil®), is a widely prescribed wake-promoting therapeutic agent. It binds competitively to the cell-membrane dopamine (DA) transporter and is dependent on catecholaminergic (dopaminergic and adrenergic) signaling for its wake-promoting effects. The clinical spectrum of effects for modafinil is distinct from the effects seen with other catecholaminergic agents. Relative to other commonly used agents that act through catecholaminergic mechanisms, modafinil has a relatively low abuse potential, produces wakefulness with an attenuated compensatory sleep recovery thereafter, and does not ameliorate cataplexy in narcolepsy. These clinically relevant phenomenological differences between modafinil and agents such as amphetamines and cocaine do not eliminate catecholaminergic effects as a possible mediator of its wake-promoting action; they merely reflect its unique pharmacological profile. Modafinil is an exceptionally weak, but apparently very selective, DA transporter inhibitor. The pharmacodynamic response to modafinil, as measured by DA levels in brain microdialyzate, is protracted relative to other agents that act via catecholaminergic mechanisms. The conformational constraints on the interaction of modafinil with the DA transporter – and probably, as a consequence, its effects on trace amine receptor signaling in the catecholaminergic cell – are unique among catecholaminergic agents. These unique pharmacological properties of modafinil should be considered both in seeking to thoroughly understand its putatively elusive mechanism of action and in the design of novel therapeutic agents.

show abstract

Section: Resultsmentioning

confidence: 99%

Modafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered Questions

Wisor¹

2013

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Other variables that might contribute to change test-retest reliability involving TMS, by influencing the basal level of neuronal activity, may include time of day (Sale et al, 2007), hormonal changes (e.g., menstrual cycle, post-menopause), level of anxiety or mood, sleep deprivation, or occult substance abuse (Rossi et al, 2009). For instance, Cohen et al (2010) found that TMS measures of plasticity can show significant diurnal changes, consistent with chronobiologic factors. Therefore, careful consideration of such factors in test-retest reliability studies is critical.…”

Section: Challenges and Advancements To Use Tms Measures Of Plasticitmentioning

confidence: 91%

Assessing brain plasticity across the lifespan with transcranial magnetic stimulation: why, how, and what is the ultimate goal?

Freitas¹,

Farzan²,

Pascual‐Leone³

2013

Front. Neurosci.

Self Cite

View full text Add to dashboard Cite

Sustaining brain and cognitive function across the lifespan must be one of the main biomedical goals of the twenty-first century. We need to aim to prevent neuropsychiatric diseases and, thus, to identify and remediate brain and cognitive dysfunction before clinical symptoms manifest and disability develops. The brain undergoes a complex array of changes from developmental years into old age, putatively the underpinnings of changes in cognition and behavior throughout life. A functionally “normal” brain is a changing brain, a brain whose capacity and mechanisms of change are shifting appropriately from one time-point to another in a given individual's life. Therefore, assessing the mechanisms of brain plasticity across the lifespan is critical to gain insight into an individual's brain health. Indexing brain plasticity in humans is possible with transcranial magnetic stimulation (TMS), which, in combination with neuroimaging, provides a powerful tool for exploring local cortical and brain network plasticity. Here, we review investigations to date, summarize findings, and discuss some of the challenges that need to be solved to enhance the use of TMS measures of brain plasticity across all ages. Ultimately, TMS measures of plasticity can become the foundation for a brain health index (BHI) to enable objective correlates of an individual's brain health over time, assessment across diseases and disorders, and reliable evaluation of indicators of efficacy of future preventive and therapeutic interventions.

show abstract

“…Yet, this effect was not shown to improve working memory performance. Eventually, repeated, daily rTMS sessions might be needed to produce changes in plasticity [e.g., (63)] and lasting effects on cognition. On the other hand, Plewnia et al (64) showed that synchronous, bifocal rTMS can induce an increase of interregional EEG coherence, which may eventually have behavioral consequences.…”

Section: Tms Paradigms To Measure Cortical Function In Schizophreniamentioning

confidence: 99%

Transcranial Magnetic Stimulation: A Neuroscientific Probe of Cortical Function in Schizophrenia

McClintock¹,

Freitas²,

Oberman³

et al. 2011

Biological Psychiatry

Self Cite

View full text Add to dashboard Cite

Transcranial magnetic stimulation (TMS) is a neuropsychiatric tool that can serve as a useful method to better understand the neurobiology of cognitive function, behavior, and emotional processing. The purpose of this paper is to examine the utility of TMS as a means of measuring neocortical function in neuropsychiatric disorders in general, and schizophrenia in particular, for the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative. When incorporating TMS paradigms in research studies, methodological considerations include technical aspects of TMS, cohort selection and confounding factors, and subject safety. Available evidence suggests benefits of TMS alone or in combination with neurophysiologic and neuroimaging methods, including positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), functional MRI (fMRI), functional near infrared spectroscopy (fNIRS), magnetoencephalography (MEG), and electroencephalography (EEG), to explore neocortical function. With the multiple TMS techniques including single-pulse, paired-pulse, paired associative stimulation, and repetitive TMS and theta burst stimulation, combined with neurophysiologic and neuroimaging methods, there exists a plethora of TMS experimental paradigms to modulate different neocortical physiologic processes. Specifically, TMS can measure cortical excitability, intracortical inhibitory and excitatory mechanisms, and local and network cortical plasticity. Coupled with functional and electrophysiological modalities, TMS can provide insight into the mechanisms underlying healthy neurodevelopment and aging, as well as neuropsychiatric pathology. Thus, TMS could be a useful tool in the CNTRICS armamentarium of biomarker methods. Future investigations are warranted to optimize TMS methodologies for this purpose.

show abstract

Enhancing plasticity through repeated rTMS sessions: The benefits of a night of sleep

Cited by 24 publications

References 54 publications

Modafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered Questions

Modafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered Questions

Assessing brain plasticity across the lifespan with transcranial magnetic stimulation: why, how, and what is the ultimate goal?

Transcranial Magnetic Stimulation: A Neuroscientific Probe of Cortical Function in Schizophrenia

Contact Info

Product

Resources

About